American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

Possible Bacterial Contamination Spurs Nasal Spray Recall

Infection Especially Dangerous in Immunocompromised, CF Patients

By News Staff

Insight Pharmaceuticals LLC has announced a voluntary recall of one lot of its Nostrilla Nasal Decongestant nasal spray because the product may be contaminated with the respiratory pathogen Burkholderia cepacia. Patients who are immunocompromised and those who have underlying pulmonary conditions -- especially cystic fibrosis -- have an increased risk for serious infection if exposed to B. cepacia.
FDA Advisory
To date, no illnesses associated with the nasal spray have been reported. The possibility of B. cepacia infection in healthy individuals is remote.

The affected lot, No 11G075, includes more than 34,000 bottles of product and was distributed to retail outlets and pharmacies nationwide. The bottles are marked with the Universal Product Code 6373673005 and bear an expiration date of 05/2014.

Consumers who have purchased Nostrilla may contact the company at (877) 546-9059, Monday through Friday from 9 a.m.-5 p.m. ET, to return the product. Consumers and health care professionals are encouraged to report adverse reactions associated with use of this product to MedWatch, the FDA's Safety Information and Adverse Event Reporting Program.

According to the Insight Pharmaceuticals website, health-related inquiries may be directed to the company at (800) 367-5423.

Share this on AAFP Connection

Search AAFP News Now

 

Health of the Public

AAFP, USPSTF Recommend Against Routine PSA Screening

Inadequate, Disordered Sleep Increases Diabetes Risk

Text Messaging Could Hike Vaccination Rates

Fluoroquinolones Tied to Greater Retinal Detachment Risk

Sanofi Announces DTaP Vaccine Shortage

AHRQ Resources Provide Ready Access to Research Data

Community-onset C. difficile Infections on the Rise

New FamilyDoctor.org Content Helps With Caring for Elderly

U.S. Measles Cases in 2011 Highest in 15 Years

FDA Warns of More Finasteride Side Effects

'Take-Back' Initiative Focuses on Destroying Unwanted Drugs

Bariatric Surgery May Help Combat Type 2 Diabetes

Certain Skin Products Tied to Mercury Poisoning

FDA Clarifies Citalopram Usage, Dosing Warnings

Veterans With PTSD at Heightened Risk for Opioid Abuse

ACP Releases Guideline on Type 2 Diabetes Management

Office Champions Seeking Applicants for Second Wave

Surgeon General Releases Report on Teen Smoking

USPSTF Issues Final Cervical Cancer Screening Recommendations

FDA Approves First Quadrivalent Influenza Vaccine

Survey: Physicians May Have Trouble Interpreting Cancer Statistics

AIM-HI Nutrition Questionnaire Can Open Dialogue

Statin, HIV/Hepatitis C Drug Interactions May Pose Risks

Statin Therapy Effective in Both Genders, Study Suggests

AAFP, CDC Announce Immunization Schedule Change

Family Physicians on Front Lines of Caring for Vets

ACIP Votes to Expand Tdap Recommendation

Recalled Oral Contraceptives Pose Pregnancy Risk

Studies Shed Light on Vaccine Side Effect Risks

Dosing Problems Prompt Recall of Infants' Tylenol Products

TB 'Superbug' Not Stateside Threat, Says FP

Adult Vaccination Coverage Remains Low, Says CDC

FDA Warns of Health Risk Tied to PPI Use

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications